Agile Therapeutics Cash Flow - Annual (NASDAQ:AGRX)

Add to My Stocks
$0.58 $0 (0%) AGRX stock closing price Jun 21, 2018 (Closing)

The Agile Therapeutics cash flow statement is one of the three reports that the company generates every quarter. While its important to look at the Agile Therapeutics debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Agile Therapeutics revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. Items like capital purchases, bank loan payments etc. which have a direct impact on the cash position of a company come out through the statemement of cash flows and help an investor who undertakes the Agile Therapeutics stock analysis. Agile Therapeutics generated $-24.56M cash from operating activities in 2017. Agile Therapeutics has a negative cash and cash equivalents change of $-12.79M.

View details of Agile Therapeutics cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec201720162015201420132012
Net Income Cash Flow
-28.3M-28.74M-30.33M-16.07M-14.32M-23.26M
Depreciation Depletion Amortization Cash-Flow------
Net Increase (Decrease) in Assets Liabilities-0.45M1.28M---0.34M-0.3M
Cash From (used in) Discontinued Operations------
Other Adjustments Net4.17M4.13M4.7M1.29M1.63M-
Net Cash from (used by) Operating Activities
-24.56M-23.3M-25.47M-14.5M-13.01M-22.96M
Increase (Decrease) in Prop Plant And Equipment-1.31M-0.03M-0.29M-0.09M-4.94M-6.69M
Acquisition Disposition of Subsidiaires------
Increase (Decrease) in Investments------
Other Cash Inflow (Outflow) from Investment Activities------
Net Cash from (used by) Investment Activities
-1.31M-0.03M-0.29M-0.09M-4.94M-6.69M
Issuance (Purchase) of Equity Shares18.68M37.86M19.92M49.81M-19.31M
Issuance (Repayment) of Debt Securities-5.61M--3M-21M
Increase (Decrease) in Bank & Other Borrowings------
Payment of Dividends & Other Cash Distributions------
Other Cash from (used by) Financing Activities--0.17M-0.42M-0.15M--0.2M
Net Cash from (used by) Financing Activities
13.07M37.68M19.98M52.66M-40.11M
Effect of Exchange Rate Changes on Cash------
Net Change in Cash & Cash Equivalents
-12.79M14.35M-5.78M38.06M-17.89M10.45M
Cash & Equivalents at Beginning of Year48.75M34.39M40.18M2.11M20.01M9.56M
Cash & Equivalents at Year End35.95M48.75M34.39M40.18M2.11M20.01M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

While Agile Therapeutics stock price history provides the price history of a stock, Agile Therapeutics stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Agile Therapeutics saw a negative change in Net Change in Cash and Cash Equivalents of $-12.79M in 2017. Apart from the Agile Therapeutics stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-24.56M for AGRX.
  • Cash Flow from investment activities: Agile Therapeutics used $-1.31M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $13.07M for Agile Therapeutics.

Key Financial Ratios For Agile Therapeutics Cash Flow